Reference

1. ^Cohen, C.; Bergis, O. E.; Galli, F.; Lochead, A. W.; Jegham, S.; Biton, B.; Leonardon, J.; Avenet, P.; Sgard, F.; Besnard, F.; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Voltz, C.; Gardes, A.; Caille, D.; Perrault, G.; George, P.; Soubrie, P.; Scatton, B. (2003). „SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation”.The Journal of Pharmacology and Experimental Therapeutics.306 (1): 407—420.PMID 12682217.doi:10.1124/jpet.103.049262. }-
2. ^Fagerström, K.; Balfour, D. J. (2006). „Neuropharmacology and potential efficacy of new treatments for tobacco dependence”.Expert Opinion on Investigational Drugs.15 (2): 107—116.PMID 16433591.doi:10.1517/13543784.15.2.107. 
3. ^Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation
4. ^Sanofi PipelineАрхивирано на веб-сајтуWayback Machine (4. децембар 2008)

Spoljašnje veze